

Gibson Dunn Advised Dianthus Therapeutics on \$288 Million Offering of Common Stock and Pre-Funded Warrants

Firm News | September 12, 2025

Gibson Dunn advised Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, on its \$288 million offering of common stock and pre-funded warrants.

Our corporate team was led by partners Ryan Murr, Branden Berns, and Melanie Neary and included associates Nicholas Linke, Jasmine Vitug, and Lauren Guzman.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Melanie E. Neary](#)

[Nicholas G. Linke](#)

[Jasmine L. Vitug](#)

[Lauren Guzman](#)

Related Capabilities

[Life Sciences](#)